STOCKS TELEGRAPH

Tag: Xenetic Biosciences

  • Why Did Xenetic Biosciences (XBIO) Stock Lost 10% In Extended Trades?

    The share price of Xenetic Biosciences Inc. (XBIO) was down -9.78% in after-hours trading at $2.86. The XBIO stock closed last session at $3.17, an increase of 4.62% or $0.14. The Xenetic Biosciences traded between $2.56 and $3.72 throughout the day. The number of XBIO stock exchanged was 13.36 million, exceeding the daily volume of 9.1 million for the past 50 days and exceeding the volume for the year to date of 3.46 million.

    XBIO stock has been declining 170.94% for the last 12 months, but has been gaining 80.11% for the past week. The XBIO stock has increased by 18.28% over the past six months, and it has increased by 49.53% over the past three months. XBIO stock is up 55.39% this year. After the private placement which was more expensive than the market, XBIO stock slumped.

    What was that private placement?

    As a biopharmaceutical company, Xenetic Biosciences, Inc. is working on XCART, a personalized CAR T platform engineered to identify patient- and tumor-specific neoantigens. In its initial research, XBIO is advancing cell-free therapeutics that target malignant B-cells on individual patients’ tumor cells for the treatment of B-cell lymphomas. A pipeline of therapeutic assets targeting oncology indications with high value can be generated by XCART.

    A healthcare-focused institutional investor has entered a definitive agreement with Xenetic Biosciences, the company announced on Monday.

    • XBIO has entered into a private placement priced at the market price of $2.70 per share to sell 4,629,630 shares of its common stock (or common stock equivalents).
    • In addition, XBIO has also agreed to issue warrants for the purchase of up to 4,628,630 shares of common stock to the investor.
    • Exercise price of the warrant to buy 4,629,630 shares of XBIO common stock is $3.30 per share.
    • When the US Securities and Exchange Commission declare the registration statement for resale of the shares of common stock issuing on exercise of the warrants as effective, the warrants will be immediately exercisable and expire three and a half years later.
    • XBIO anticipates closing the offering by July 28, 2021, assuming all customary closing conditions are satisfied.
    • The placement agent for XBIO’s offering was H.C. Wainwright & Co.

    What is likely to be the net proceeds for XBIO Stock?

    Xenetic (XBIO) is expected to receive approximately $12.5 million gross proceeds from the offering before deducting placement agent fees. A fully exercised set of warrants would generate approximately $15.3 million in gross proceeds. Net proceeds from the offering will be used to support XBIO’s general working capital needs.

  • Why Xenetic Biosciences Inc. (XBIO) stock is surging in the Monday’s pre-market??

    Xenetic Biosciences Inc. (XBIO) stock surged 24.21% in Monday’s pre-market as of this writing. In the regular trading session on Friday, XBIO’s stock gained 35.48%. XBIO shares have risen 108.26% over the last 12 months, and they have moved up 42.37% in the past week. Over the past three months, the stock has gained 29.90%, while over the past six months, it has shed 4.18%. Further, the company has a current market of $16.30 million and its outstanding shares stood at 8.75 million.

    Recent XBIO financial results announcement

    On May 12, 2021, Xenetic Biosciences, Inc reported its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • The company suffered a net loss of approximately $1.3 million in Q1 2021
    • Research & development expenses were $0.6 million compared to $0.4 million in the comparable quarter in 2020.
    • General and administrative expenses were$0.9 million in Q1 2021 which were the same in Q1 2020.

    XBIO Participation in the recent investor conference

    Xenetic Biosciences recently participated at Q2 Virtual Investor Summit which was held on Tuesday, May 18, 2021. The company was presented by Chief Executive Officer Jeffrey Eisenberg presented the company during the event.

    Commencing Exploratory Study of XCART

    On March 29, 2021, Xenetic Biosciences, Inc received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART.

    The study will be conducted at the Vitebsk Regional Clinical Oncological Center in Minsk, Belarus, and will enrol adult B-Cell NHL patients. The collaborations being leveraged in the XCART development program may be expanded to include the development and qualification of manufacturing processes for producing autologous XCART T-Cells. The work being performed under these collaborations is expected to position the Company to conduct IND-enabling studies in the United States.

    XBIO Q4 & FY 2020 financial results

    On March 17, 2021, Xenetic Biosciences, Inc announced its financial results for the fourth quarter and full-year 2020.

    FY 2020 financial highlights

    • The company suffered a net loss of approximately $10.9 million in FY 2020.
    • For FY 2020, R&D expenses were $1.7 million compared to $4.9 million for the year ended December 31, 2019.
    • General and administrative expenses were $3.4 million from $4.7 million in the comparable period in 2019.
    • Working capital was approximately $11.4 million in FY 2020 compared to $9.7 million on December 31, 2019.
    • The Company ended the year with approximately $11.5 million of cash.

    Conclusion

    The recent Monday pre-market and Friday surge of XBIO stock has no grounds. There is no recent news or development which could be linked with Friday’s performance. We hope that it will commence the new week in a positive mode.

  • Why is Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares price dipping low in the pre-marketing session?

    Why is Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares price dipping low in the pre-marketing session?

    Xenetic Biosciences, Inc. (NASDAQ: XBIO) plummeted in the early morning trading session following, a biopharmaceutical corporation focused on the development of XCARTTM, a customized CAR T technology platform designed to target neoantigens unique to patients and tumors, recently announced that it has entered into a stock purchasing agreement with many retail and approved investors to purchase and sell 2,448,980 shares of the Company. Before deducting placement agent commissions and other offering costs incurred by Xenetic, the offering is expected to result in gross proceeds to Xenetic of approximately $6.0 million.

    The Corporation plans to use the gross profits of this sale for general corporate purposes, working capital, and the creation of the Company’s differentiated, patented approach to customized CAR T therapy for the treatment of various forms of B-cell Non-Hodgkin lymphomas for the advancement of the XCARTTM platform.

    Xenetic Biosciences (XBIO) dipped -17.35% to reach $2.63 in the Pre-market session.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.